Abstract
A Global ADHD Working Group of experienced clinicians and researchers was gathered to review the latest evidence, discuss current best practice in the treatment of attention-deficit/hyperactivity disorder (ADHD), and make a statement based on consensus. The statement aims to re-affirm ADHD as a valid disorder that exists across different cultures, has a significant global impact, and should be diagnosed and effectively treated wherever it occurs.
ADHD is one of the most common neurobehavioural disorders of childhood and impacts on many aspects of development, including social, emotional and cognitive functioning, in the home and school environment. Although these findings are from developed countries, the impact in developing countries is likely to be similar.
There is strong supportive evidence for the validity of ADHD as a syndrome with neurobiological aspects, and complex genetic factors are primarily implicated in the aetiology. Accurate diagnosis and measurement of impairment is important to enable appropriate and successful management of symptoms. ADHD is a persistent condition that needs to be treated and monitored over time. The evidence supporting medication-based interventions (such as methylphenidate) is strong and consensus treatment algorithms to guide the multimodal treatment of ADHD, alone and in combination with common comorbidities, are suggested.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
AACAP (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(Suppl 2):26S–49S
AAP (2000) Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105(5):1158–1170
AAP (2001) Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108(4):1033–1044
APA (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Association. Washington, DC
Barkley RA (1990) Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment. Guilford Press. New York
Barkley RA (2002) International Consensus Statement on ADHD. J Am Acad Child Adolesc Psychiatry 41(12):1389
Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport JL (1997) Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. JAACAP 36(5):589–596
Faraone SV (2000) Genetics of childhood disorders: XX. ADHD, Part 4: is ADHD genetically heterogeneous? J Am Acad Child Adolesc Psychiatry 39(11):1455–1457
Hinshaw S, Klein R, Abikoff H (1998) Childhood attention deficit hyperactivity disorder: Nonpharmacological and combination treatments. In: Nathan PE, Gorman JM (eds) A Guide to Treatment That Work. Oxford University Press. New York, pp 24–61
Kutcher S, Aman M, Brooks SJ, BuitelaarJ, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004) International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14(1):11–28
MTA (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: the multimodal treatment study of children with ADHD. Arch Gen Psychiatry 56(12):1073–1086
Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, Mc-Cracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, Toprac MG (2000) The Texas Children’s Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part II: Tactics. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 39(7):920–927
Santosh P (2002) Multimodal treatment study of ADHD (MTA): Impact of classificatory systems on pharmacological interventions. Presented at 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, October 22–27, 2002
SIGN (2001) Attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline. No. 52. Scottish Intercollegiate Guidelines Network. Edinburgh, UK
WHO (1992) World Health Organisation. International Classification of Diseases, 10th Edition
Author information
Authors and Affiliations
Corresponding author
Additional information
by the Global ADHD Working Group*
* Members of the Global ADHD Working Group Cornelio Banaag Jr., Philippines; François Bange, France; Manuel Bouvard, France; F. Xavier Castellanos, USA; David Coghill, UK; Jesus Gomez-Plascencia, Mexico; Laurence Greenhill, USA; Michael Huss, Germany; Helmut Remschmidt (Chair), Germany; Luis Rohde,Brazil; Paramala Santosh,UK; Martin Schmidt, Germany; Yee-Jin Shin, South Korea; Eric Taylor, UK and Kenneth Whiting, Australia.